Sector News

CVC talks Alvogen sale with Shanghai

September 26, 2017
Life sciences

Amid a wave of consolidation prompted by pricing pressures on the generics industry, another sale is brewing.

The private equity owners of Alvogen—which include CVC Capital Partners—are weighing their options for the New Jersey drugmaker, which could be valued at about $4 billion, Bloomberg reports. And a sale of Alvogen’s U.S. business to Shanghai Pharmaceuticals Holding Co. is on the table.

CVC and its fellow controlling shareholders—who nabbed their stake in a 2015 deal that valued Alvogen at $2 billion—have held on-and-off talks with Shanghai, the news service notes. Though while they’re not formally putting the company up for auction, they may hold talks with other international suitors.

Under a potential Shanghai transaction, Alvogen would hang onto its operations in Asia and Europe, which include Alvogen Korea Co., a plant in Romania, and a packaging center in Serbia. Shanghai, though, would pick up Alvogen’s biggest market, where it sells generics in therapeutic areas such as oncology, cardiology and neurology and provides third-party services including contract manufacturing in clinical research.

For Shanghai, the buy would be a boost in the wake of a failed play for German generics maker Stada, which is going through the sale process with private equity partners Bain Capital and Cinven. Sources have told Bloomberg the company is also currently bidding for a stake in Atlanta’s Arbor Pharmaceuticals and Cardinal Health’s Chinese distribution business.

For years, Alvogen, launched and helmed by former Actavis executive Robert Wessman, has said it’s angling to become a top-tier generics player. The CVC-led deal seemed to further that aim, with Wessman touting his company’s new access to “significant experience and additional resources” to pump up growth.

Times have grown increasingly tough for generics competitors over the last couple of years, prompting some, such as Stada, to consider selling. Others—particularly in the industry’s top ranks—have gone for scale instead and made buys of their own, with Teva forking over $40.5 billion for Allergan’s generics arm and Mylan shelling out $5.7 billion for Abbott Laboratories’ ex-U.S. copycat business.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).